<DOC>
	<DOCNO>NCT01654146</DOCNO>
	<brief_summary>The purpose study determine weekly chemotherapy ( i.e . give paclitaxel carboplatin low dose every week ) effective standard chemotherapy ( paclitaxel carboplatin give every three week 18 week ) treat ovarian cancer . The investigator also want see weekly chemotherapy cause few side-effects standard chemotherapy .</brief_summary>
	<brief_title>ICON8 : Weekly Chemotherapy Ovarian Cancer</brief_title>
	<detailed_description>ICON8 three-arm , three stage trial . Patients randomise 1:1:1 ratio . Patients arm 1 ( control arm ) receive weekly carboplatin paclitaxel day 1 21-day cycle 6 cycle . Patients arm 2 receive carboplatin day 1 dose-fractionated weekly paclitaxel day 1 , 8 15 21-day cycle 6 cycle . Patients arm 3 receive dose-fractionated weekly carboplatin dose-fractionated weekly paclitaxel day 1 , 8 15 21-day cycle 6 cycle . The trial three plan stage . Stage 1 conduct confirm feasibility safety protocol treatment patient separately Delayed Primary Surgery ( DPS ) patient . The outcome measure stage 2 9-month progression-free survival ( PFS ) rate . The primary outcome measure stage 3 PFS overall survival secondary outcome toxicity , Quality Life Health Economics . If pre-defined level deliverability , stage 1 , activity , stage 2 , meet research arm reconsider .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Females age 18 year Signed informed consent ability comply protocol Histologically confirm , core biopsy disease site minimum requirement ( cytology alone insufficient diagnosis ) : Epithelial ovarian carcinoma Primary peritoneal carcinoma Müllerian histological type Fallopian tube carcinoma FIGO stage IC , may base clinical radiological assessment patient undergone immediate primary surgery Confirmed highrisk histological subtype patient FIGO stage IC/IIA disease , namely : High grade serous carcinoma Clear cell carcinoma Other histological subtype consider poorly differentiated/grade 3 ECOG Performance Status ( PS ) 02 Life expectancy &gt; 12 week Adequate bone marrow function : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/l Platelets ( Plt ) ≥ 100 x 109/l Haemoglobin ( Hb ) ≥ 9g/dl ( post transfusion ) Adequate liver function ( within 28 day prior randomisation ) : Serum bilirubin ( BR ) ≤ 1.5 x ULN Serum transaminases ≤ 3 x ULN absence parenchymal liver metastases ≤ 5 x ULN presence parenchymal liver metastases Adequate renal function define GFR ( Glomerular Filtration Rate ) ≥ 30ml/min . Nonepithelial ovarian cancer , include malignant mixed Müllerian tumour ( carcinosarcoma ) Peritoneal cancer Müllerian origin , include mucinous histology Borderline tumour ( tumour low malignant potential ) Prior systemic anticancer therapy ovarian cancer ( example chemotherapy , monoclonal antibody therapy , tyrosine kinase inhibitor therapy hormonal therapy ) Previous malignancy within 5 year prior randomisation apart : adequately treat carcinoma insitu cervix , breast ductal carcinoma insitu , nonmelanomatous skin cancer ; previous/synchronous earlystage endometrial cancer define stage IA ( FIGO 2009 ) grade 1 2 endometrioid cancer lymphovascular space invasion Preexisting sensory motor neuropathy grade ≥ 2 Evidence disease/metabolic dysfunction opinion investigator would put subject highrisk treatmentrelated complication prevent compliance trial protocol Planned intraperitoneal cytotoxic chemotherapy Any previous radiotherapy abdomen pelvis Sexually active woman childbearing potential willing use adequate contraception ( e.g . oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly surgically sterile ) study duration least six month afterwards Pregnant lactate woman Treatment investigational agent prior protocol defined progression Known hypersensitivity carboplatin , paclitaxel excipients ( include cremophor ) History clinical suspicion brain metastasis spinal cord compression . CT/MRI brain mandatory case suspect brain metastasis . Spinal MRI mandatory case suspect spinal cord compression . Patients brain meningeal metastasis eligible</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Epithelial ovarian carcinoma</keyword>
	<keyword>Fallopian tube carcinoma</keyword>
	<keyword>Primary serous peritoneal carcinoma</keyword>
	<keyword>Gynaecological carcinoma</keyword>
	<keyword>Randomised control trial</keyword>
</DOC>